McKesson Q3 FY25: where the revenue came from and where it went
The whole income statement of McKesson for this quarter, as one diagram: what earned the revenue, and what it went on.
- Period
- Oct 1 – Dec 31, 2024
- Reported
- Feb 6, 2025
Revenue$95.29B
+18% year over year
Gross profit$3.28B
3% margin
Operating profit$1.22B
1% margin
Net profit$0.88B
1% margin
The numbers
| Item | Value | Share of revenue | Year over year |
|---|---|---|---|
| Revenue | 95.29 | 100% | +18% |
| U.S. pharmaceutical | 87.11 | 91% | |
| International | 3.86 | 4% | |
| Medical-Surgical | 2.95 | 3% | |
| Prescription technology | 1.37 | 2% | |
| Cost of revenue | −92.01 | 97% | |
| Gross profit | 3.28 | 3% margin | +0pp |
| SG&A | −2.03 | 2% | −1pp |
| Other | −0.03 | 0% | +0pp |
| Operating profit | 1.22 | 1% margin | +0pp |
| Tax | −0.35 | ||
| Net profit | 0.88 | 1% margin | +0pp |
124 of 418 companies, most recently reported first
New results in your inbox
When a big company reports, we send you a link to its diagram before anyone has time to comment on it. This is a mailing list, not an account: it does not open the diagrams by itself. No spam, one-click unsubscribe.
Drag or use the arrow keys to see the rest